Background: Vinorelbine is an active drug in the treatment of lung and breast cancers and has a favorable toxicity profile. Many clinical trials have demonstrated its antitumor activity in other tumor types including squamous cell carcinoma of the head and neck (SCCHN). We investigated the efficacy and tolerability of vinorelbine in patients with recurrent and/or metastatic SCCHN, previously untreated by chemotherapy.
Introduction
Squamous-cell carcinoma of the head and neck (SCCHN) is one of the most common tobacco-related tumors, with a worldwide incidence of about 500,000 new cases per year [1] . The majority of patients have, at diagnosis, very advanced primary and nodal involvement disease (stage III-IV WHO). Despite the use of optimal local treatment by surgical and radiotherapeutic techniques, the prognosis of these patients is poor; only 30% are alive at five years and not all will be disease-free; 50%-60% of these patients will develop a locoregional recurrence and about 30% distant metastases [2] [3] [4] .
At present the treatment for recurrent and metastatic SCCHN is palliative. Chemotherapy is considered the standard therapy for this patient population. The survival is usually six to 10 months and is not affected by the use of chemotherapy. Consequently these patients can be eligible for new drugs or new combination chemotherapy regimens performed in clinical trials [5, 6] .
Vinorelbine (Navelbine®) is a semisynthetic vincaalkaloid with a wide spectrum of activity against both animal and human tumors. Like other vinca-alkaloids, vinorelbine stops mitosis by inhibition mitotic microtubular assembly during metaphase. However, in preclinical studies, vinorelbine appeared to be more active than vinblastine and vincristine and its effect on axonal microtubules is limited, and neurotoxicity is thus decreased. The dose-limiting toxicity of vinorelbine is granulocytopenia [7] [8] [9] [10] . Currently, vinorelbine is in routine clinical use in breast and lung cancers. Clinical trials have shown efficacy for vinorelbine in many other tumors including head and neck cancer [10] [11] [12] [13] [14] [15] .
We performed a phase II study to evaluate the efficacy and the tolerance of vinorelbine in advanced, recurrent and/or metastatic SCCHN. The efficacy of vinorelbine in tumor targets within or outside previously irradiated fields and the determination of dose intensity were the second aims of this study.
Patients and methods

Patient selection
The eligibility criteria included a histologically-confirmed advanced, recurrent and/or metastatic SCCHN, definitely not accessible to a Evaluation of response Tumor response was measured according to WHO criteria [16] . A first assessment was performed after eight weeks of treatment (regardless of the number of vinorelbine injections) and then every eight weeks or as indicated by new symptoms. The patients with complete radiologic response and with microscopic disease on endoscopic biopsies were considered to be in partial remission. All radiological examinations and CT scans were reviewed by an independent radiologist and all tumor responses were confirmed by an investigator's panel discussion.
Statistical methods
Confidence intervals for response rates were calculated using the normal approximation of binomial distribution. Statistical analysis of frequency data relied on Yates'corrected chi-square test. Dose intensity was performed by the Hryniuk method [17] . The calculation of survival probability was assessed using the Kaplan-Meier method. The onesample multiple testing procedure for phase II clinical trials described by Fleming [18] with the minimum desirable response rate of 20% has been used for each of the two groups of patients (targets within or outside previously irradiated fields).
Results
loco-regional treatment, with at least one bidimensionally measurable lesion within or outside previously irradiated fields, of which the larger diameter was >2.5 cm (lung lesions >2.0 cm) evaluated by physical examination, endoscopy, CT scan or chest X-ray; no chemotherapy except prior neoadjuvant or adjuvant chemotherapy providing a sixmonth washout time between the last treatment and inclusion in the study; a minimum of four weeks between the end of the prior radiotherapy and entry into the study; patients were required to be between 18 and 75 years old, to have a performance status (WHO) ^2 , and initial blood parameters as follows: neutrophils > 2 x 10 9 /l, platelets > 100 x 10 9 /l, normal hepatic function: serum total bilirubin < 1.5 x N, alkaline phosphatase, ASATand ALAT <2.5 x N (except the liver involvement); and to give informed written consent. Patients were excluded if they had an undifferentiated or non-keratinizing carcinoma, tumor of the nasal or paranasal cavity or of the nasopharynx; only evaluable or unidimensional lesions, other previous or concurrent malignancies, leptomeningeal metastatic disease, uncontrolled hypercalcemia and/or infection, concurrent treatment with colony-stimulating factors or conticosteroids.
Treatment
Vinorelbine was administered at a dose of 30 mg/m 2 /week i.v. Patients were treated by short-duration infusion on an out-patient basis. The same schedule is used routinely in the treatment of breast and lung cancer. The use of a central venous line was recommended for safe administration of vinorelbine.
The patients received vinorelbine until disease progression or the occurrence of unacceptable toxicity. Evaluation during therapy included weekly physical examination and vital signs, complete blood counts on day 7 of each cycle before the start of the next cycle of treatment, and monthly measurement of serum electrolytes and chemistry profiles of the hepatic and renal functions. No dose reduction of vinorelbine was allowed. If on day 1 of treatment the neutrophil count was < 1.0 x 1O Between February 1995 and March 1997, 71 patients in eight institutions, were enrolled into this ECSG-EORTC (Early Clinical Studies Group of EORTC) study. Eight patients were ineligible because of prior chemotherapy for advanced disease, concurrent malignancy, only unidimensionally measurable lesions and/or patient refusal (no written consent); none of them had disease progression at the time of exclusion from the study. The characteristics of the 63 eligible patients are summarized in Table 1 .
Efficacy
Seven of the 63 eligible patients were not evaluable for tumor response because their lesions were not measured before discontinuation: two early deaths (toxicity, nonmalignant disease), three patient refusals after starting treatment and two early discontinuations due to toxicity (no clinical evidence of disease progression).
Among the 56 patients evaluable for tumor response there were two complete responses (CR) and seven partial responses (PR), for an overall response rate (OR) of 16% (95% CI: 8%-28%). Taking into account all 63 of the eligible patients, the overall response rate was 14% (95% CI: 7%-25%). Two complete tumor responses (oropharynx, tongue) were confirmed by negative biopsies. One patient with local recurrence of oropharyngeal carcinoma pretreated initially by radiotherapy (diseasefree interval (DFI): 31 months) achieved CR after 16 cycles of vinorelbine. The duration of overall response was 28 weeks (CR: 10 weeks). The second patient had a locoregional recurrence of a tongue carcinoma previously treated by radiotherapy and surgery (DFI: six months). We observed a CR after 28 cycles of vinorelbine (tongue and submandibular lymph node) with a (17) 3 (4) 12 (17) 7 (10) 12 (17) 17 (25) 4 (6) 11 (16) 18 (26) 3 (4) 3 (4) Grade 2 12 (17) 10 (14) 1 (1) Among seven patients who achieved a PR, there were two with local recurrences of hypopharyngeal carcinoma pretreated by surgery and radiotherapy (DFI: 20 months) and by chemotherapy and radiotherapy (DFI: 29 months), the duration of PR was 18 and 12 weeks, respectively. Three others patients with local or locoregional recurrences of oropharyngeal carcinoma (oropharynx, lymph nodes, mandibular skin) previously treated by radiotherapy or by surgery and radiotherapy (DFI: five, six and 15 months) obtained PR lasting 12,19 and 23 weeks, respectively. These seven patients (two CR + five PR) with locoregional recurrences had lesions in previously irradiated fields. Two further patients who achieved PR had targets only outside irradiated fields, lung metastases (without locoregional recurrence) of carcinoma of the oral cavity or of the oropharynx cured by radiotherapy or chemotherapy and radiotherapy (DFI: 14 and 15 months), the durations of PR were 16 and 25 months, respectively.
The overall response rate was 19% (95% CI: 8%-36%) for 36 evaluable patients with lesions in previously irradiated fields. For the 20 evaluable patients with lesions only outside previously irradiated fields the overall response rate was 10% (95% CI: l%-32%) ( Table 3) .
The median duration of responses was 19 (12-63) weeks. Eighteen patients (32%) had stable disease (for a minimum of eight weeks) and 29 patients (52%) had disease progression (DP) including two early deaths due to DP. The median time to progression for all eligible patients was 12 weeks (Figure 1 ) and the median survival duration was 32 weeks (Figure 2) .
Toxicity
Sixty-nine of the 71 included patients were evaluable for toxicity (Table 2 ) using CALGB criteria [19] . Hematologic toxicity, essentially neutropenia, was acceptable. Leukopenia of grade 3-4 was seen in 35 (51%) patients and neutropenia (grade 3-4) in 37 (53%) patients. Only one patient had thrombocytopenia (grade 2) and 11 (16%) patients had anemia of grade 3-4. The median nadir of leukocytes was 1.9 x 10 9 /l (0.6-9.8) and of neutrophils 0.9 x 10 9 /l (0.0-9.1). Hematopoietic growth factors were not given. Thirty-two patients (46%) developed infection, in most cases bronchopulmonary, requiring an intensive antibiotic treatment and/or hospitalization in 12 (17%) patients. There were two early deaths due to infection: one patient developed a septic shock following diarrhea and fever and died on day 5 of the second cycle of treatment (neutropenia was not demonstrated because the sample was not evaluable) and one patient died of pneumopathy due to malignant disease (after three cycles of treatment). Nausea, vomiting, stomatitis and peripheral sensory neuropathy were mild and infrequent. Constipation was observed in 31 patients (45%), four of them developed a paralytic ileus which recovered with symptomatic treatment. Jaw pain and/or acute pain at oral and oropharyngeal tumor sites occurred in 15 patients (21%) and required morphine therapy during vinorelbine infusions in eight patients. Anorexia and asthenia were the most frequent flu-like symptoms. No pulmonary toxicity and no chest pain were observed.
Treatment and dose intensity
A total of 530 cycles of vinorelbine were given to the 63 eligible patients. The median number of cycles was 7 . No dose reduction of vinorelbine was performed. One hundred seventeen cycles (22%) were delayed (#; 3 days), in 72 cycles (14%) the delay was due to hematologic toxicity (62% of all delays). The median dose intensity was 85% (range 57%-104%) and the median received dose of vinorelbine was 25.5 mg/m 2 /week (17-31.5).
Discussion
The prognosis for patients with recurrent or metastatic SCCHN remains poor. Chemotherapy has been used extensively in these patients. Many anticancer drugs have been identified as active in patients with recurrent or metastatic SCCHN. Methotrexate, cisplatin, carboplatin, bleomycin and 5-fluorouracil (5-FU) are the most efficient cytotoxic agents commonly used in patients with recurrent or metastatic SCCHN. Among the new drugs, paclitaxel and docetaxel have demonstrated the most promising activity in these patients. The overall response rates to each of these cytotoxic agents ranges between 10% to 40% in phase II studies but more recent randomized trials reported the overall response rates less than 20% for methotrexate, cisplatin and 5-FU. Treatment with combination chemotherapy results in higher response rates than single agents (30%-40% vs. 10%-20%, respectively) without clearly improving survival; complete responses are rare, duration of responses is usually short (four to six months) and the median survival is approximately six months [2] [3] [4] [5] [6] [20] [21] [22] [23] [24] [25] .
The results of our multicenter phase II study suggest that vinorelbine is an active drug in recurrent and/or metastatic SCCHN. In this study of 56 evaluable patients, the overall response rate was 16% with two CR and seven PR, and the median duration of responses was five months. We observed more responses in locoregional recurrences in previously irradiated fields (19%) than in distant metastases (10%); we have not any clear explanation for these findings. Our results appear comparable to the pilot study of vinorelbine in recurrent or metastatic SCCHN published by Gebbia et al. [14] . In 23 chemotherapy-naive patients Gebbia et al. reported five PR (the response rate of 22%). Testolin et al. [15] obtained only one PR in 15 heavily pretreated patients with recurrent and metastatic SCCHN (all patients received prior chemotherapy), and vinorelbine was given at a lower dose of 20 mg/m 2 /week. Canfield et al. [26] observed four PR in 32 evaluable patients with recurrent/metastatic SCCHN in an American phase II study.
The main toxicity observed in our study was neutropenia, which constituted the major reason of all treatment delays. Severe short lasting neutropenia (grade 3-4) occurred in about half of the patients, no colony stimulating factors were administered. Among the complications, bronchopulmonary infections remain frequent in patients with locoregional recurrent and metastatic SCCHN. These infections appeared frequently in this study, 12 patients developed severe infections, two of them died. The peripheral sensory neuropathy was mild and rare. Constipation (autonomic neuropathy) was more frequent, probably worsened by concomitant morphine therapy in four patients, who developed a paralytic ileus, however they recovered rapidly with standard treatement. Acute pain at the tumor site and/ or jaw pain during vinorelbine infusions were severe in eight patients, who required morphine injections. Gebbia et al. [27] reported a similar experience with this acute pain syndrome, of which the physiopathological mechanism remains unclear. Gastrointestinal toxicities and asthenia were frequent but mild or moderate.
The median relative dose intensity of vinorelbine obtained in this study was 85% (25.5 mg/m 2 /week). Regarding the observed tolerance (neutropenia of grade 3-4 in 53% of patients) and this dose intensity, the chosen dose of vinorelbine, 30 mg/m 2 /week, seems to be the optimal dose for this patient population.
In conclusion, vinorelbine is a drug with documented antitumor activity and acceptable toxicity at the dose and schedule administered in this study in patients with recurrent and /or metastatic SCCHN. In future, combined research will be essential to identify more active combination chemotherapy and concomitant chemoradiotherapy regimens in the treatment of SCCHN. The favorable toxicity profile of vinorelbine, its demonstrated efficacy and possible therapeutic synergy with other drugs and/or its radiosensitizing effect offer opportunities for ongoing and future development of vinorelbine.
